Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study | Cardiovascular Diabetology
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with a significantly increased risk of cardiovascular…